Whole-body MR imaging vs. FDG-PET: Comparison of accuracy of M-stage diagnosis for lung cancer patients

Journal of Magnetic Resonance Imaging

Volumn 26, Issue 3, 2007, Pages 498-509

  Ohno, Yoshiharu ^a   Koyama, Hisanobu ^a   Nogami, Munenobu ^a   Takenaka, Daisuke ^a   Yoshikawa, Takeshi ^a   Yoshimura, Masahiro ^a   Kotani, Yoshikazu ^a   Nishimura, Yoshihiro ^a   Higashino, Takanori ^a,b   Sugimura, Kazuro ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TENRI HOSPITAL   (Japan)

Author keywords

Contrast media; Lung cancer; Metastases; MR; PET; Staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; BONE METASTASIS; CANCER DIAGNOSIS; CANCER PATIENT; DIAGNOSTIC ACCURACY; FEMALE; HEAD AND NECK CANCER; HUMAN; INTERMETHOD COMPARISON; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; ROC CURVE; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; WHOLE BODY MRI; ARTICLE; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; LUNG TUMOR; METHODOLOGY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; REPRODUCIBILITY; WHOLE BODY IMAGING;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM METASTASIS; REPRODUCIBILITY OF RESULTS; ROC CURVE; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 35248821350     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.21031     Document Type: Review

References (34)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Melamed MR, Flehinger BJ, Zaman MB. Impact of early detection on the clinical course of lung cancer. Surg Clin North Am 1987;67: 909-924.
3. Deslauriers J. Current surgical treatment of nonsmall cell lung cancer 2001.Eur Respir J Suppl 2002;35:S61-S70.
4. Krupnick AS, Kreisel D, Hope A, Bradley J, Govindan R, Meyers B. Recent advances and future perspectives in the management of lung cancer. Curr Probl Surg 2005;42:540-610.
5. Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 1973;4:31-42.
6. Clark R, Ihde DC. Small-cell lung cancer: treatment progress and prospects. Oncology 1998;12:647-658.
7. Marom EM, McAdams HP, Erasmus JJ, et al. Staging non-small cell lung cancer with whole-body PET. Radiology 1999;212:803-809.
8. Pieterman RM, van Putten JW, Meuzelaar JJ, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000;343:254-261.
9. Chin R Jr, McCain TW, Miller AA, et al. Whole body FDG-PET for the evaluation and staging of small cell lung cancer: a preliminary study. Lung Cancer 2002;37:1-6.
10. Silvestri GA, Tanoue LT, Margolis ML, Barker J, Detterbeck F; American College of Chest Physicians. The noninvasive staging of non-small cell lung cancer: the guidelines. Chest 2003;123:147S-156S.
11. Kamel EM, Zwahlen D, Wyss MT, Stumpe KD, von Schulthess GK, Steinert HC. Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer. J Nucl Med 2003;44: 1911-1917.
12. Aquino SL, Fischman AJ. Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer? Chest 2004;126:755-760.
13. Walker R, Kessar P, Blanchard R, et al. Turbo STIR magnetic resonance imaging as a whole-body screening tool for metastases in patients with breast carcinoma: preliminary clinical experience. J Magn Reson Imaging 2000;11:343-350.
14. Daldrup-Link HE, Franzius C, Link TM, et al. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. AJR Am J Roentgenol 2001;177:229-236.
15. Barkhausen J, Quick HH, Lauenstein T, et al. Whole-body MR imaging in 30 seconds with real-time true FISP and a continuously rolling table platform: feasibility study. Radiology 2001;220:252-256.
16. Mazumdar A, Siegel MJ, Narra V, Luchtman-Jones L. Whole-body fast inversion recovery MR imaging of small cell neoplasms in pediatric patients: a pilot study. AJR Am J Roentgenol 2002;179: 1261-1266.
17. Lauenstein TC, Goehde SC, Herborn CU, et al. Whole-body MR imaging: evaluation of patients for metastases. Radiology 2004; 233:139-148.
18. Korobkin M, Lombardi TJ, Aisen AM, et al. Characterization of adrenal masses with chemical shift and gadolinium-enhanced MR imaging. Radiology 1995;197:411-418.
19. Yokoi K, Kamiya N, Matsuguma H, et al. Detection of brain metastasis in potentially operable non-small cell lung cancer: a comparison of CT and MRI. Chest 1999;115:714-719.
20. Earnest F, 4th, Ryu JH, Miller GM, et al. Suspected non-small cell lung cancer: incidence of occult brain and skeletal metastases and effectiveness of imaging for detection - pilot study. Radiology 1999; 211:137-145.
21. Remer EM, Obuchowski N, Ellis JD, Rice TW, Adelstein DJ, Baker ME. Adrenal mass evaluation in patients with lung carcinoma: a cost-effectiveness analysis. AJR Am J Roentgenol 2000;174:1033-1039.
22. Rohren EM, Provenzale JM, Barboriak DP, Coleman RE. Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy. Radiology 2003;226:181-187.
23. Svanholm H, Starklint H, Gundersen HJ, Fabricius J, Barlebo H, Olsen S. Reproducibility of histomorphologic diagnoses with special reference to the kappa statistic. APMIS 1989;97:689-698.
24. Griffeth LK, Rich KM, Dehdashti F, et al. Brain metastases from non-central nervous system tumors: evaluation with PET. Radiology 1993;186:37-44.
25. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology 2004;231:305-332.
26. Vansteenkiste JF. PET scan in the staging of non-small cell lung cancer. Lung Cancer 2003;42:S27-S37.
27. DeVita VT Jr, Young RC, Canellos GP. Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer. Cancer 1975;35:98-110.
28. Liotta LA, Kleinerman J, Saidel GM. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 1974;34:997-1004.
29. Rak JW, St Croix BD, Kerbel RS. Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs 1995;6:3-18.
30. Antoch G, Stattaus J, Nemat AT, et al. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology 2003; 229:526-533.
31. Shim SS, Lee KS, Kim BT, et al. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology 2005;236:1011-1019.
32. Halpern BS, Schiepers C, Weber WA, et al. Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion. Chest 2005;128:2289-2297.
33. Bruzzi JF, Munden RF. PET/CT imaging of lung cancer. J Thorac Imaging 2006;21:123-136.
34. Endo K, Oriuchi N, Higuchi T, Iida Y, et al. PET and PET/CT using (18)F-FDG in the diagnosis and management of cancer patients. Int J Clin Oncol 2006;11:286-296.